WuXi Biologics (Cayman) Inc WXIBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $6.28
- Day Range
- $5.87–6.66
- 52-Week Range
- $3.90–7.49
- Bid/Ask
- $6.05 / $6.78
- Shares Outstanding
- 4.12B
- Market Cap
- $25.61B
- Volume/Avg
- 3,555 / 4,417
Key Statistics
- Price/Earnings (Normalized)
- 32.34
- Price/Sales
- 8.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.86%
Company Profile
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing, refining, and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 13,252
- Website
- https://www.wuxibiologics.com
Competitors
Valuation
|
Metric
|
WXIBF
|
IQV
|
CRL
|
|---|---|---|---|
Price/Earnings (Normalized) | 32.34 | 20.90 | 30.20 |
Price/Book Value | 3.97 | 6.95 | 5.03 |
Price/Sales | 8.06 | 2.61 | 3.65 |
Price/Cash Flow | 21.88 | 16.94 | 21.27 |
Price/Earnings
WXIBF
IQV
CRL
Financial Strength
|
Metric
|
WXIBF
|
IQV
|
CRL
|
|---|---|---|---|
Quick Ratio | 2.64 | 0.62 | 0.80 |
Current Ratio | 3.32 | 0.71 | 1.35 |
Interest Coverage | 67.52 | 2.99 | −0.77 |
Quick Ratio
WXIBF
IQV
CRL
Profitability
|
Metric
|
WXIBF
|
IQV
|
CRL
|
|---|---|---|---|
Return on Assets (Normalized) | 10.38% | 7.22% | 6.50% |
Return on Equity (Normalized) | 14.65% | 34.41% | 15.51% |
Return on Invested Capital (Normalized) | 11.25% | 12.37% | 9.46% |
Return on Assets
WXIBF
IQV
CRL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>zV>LHj | LOCK|sR@@@ | $126B | |||
| Moderna Inc
MRNA
| LOCK|^#fj<@W | LOCK|Q$ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|FyNV#z | LOCK|!J>sN | $80B | |||
| argenx SE ADR
ARGX
| LOCK|F#L#LC | LOCK|Chq | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>mBr#k& | LOCK|j&? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hlZk&%L | LOCK|SNHc& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<Z!$<!!^ | LOCK|GmT%n | $26B | |||
| Incyte Corp
INCY
| LOCK|@Cg?jM | LOCK|g^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|JL>^JBK | LOCK|kh | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!wZ&%N! | LOCK|^z | $14B |
United States